This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Clarson, C. L.
Right arrow Articles by Del Maestro, R. F.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Clarson, C. L.
Right arrow Articles by Del Maestro, R. F.
Related Collections
Right arrow Endocrinology

PEDIATRICS Vol. 103 No. 3 March 1999, p. e37

ELECTRONIC ARTICLE:
Growth Failure After Treatment of Pediatric Brain Tumors

Received Jul 7, 1998; accepted Nov 12, 1998.

Cheril L. Clarson* and Rolando F. Del MaestroDagger

From the * Department of Pediatrics and the Dagger  Brain Research Laboratory, Clinical Research Unit, Division of Neurosurgery, Department of Clinical Neurological Sciences, Children's Hospital of Western Ontario, London, Ontario, Canada.

Objectives.  Primary brain tumors are the most common solid tumors that occur in childhood. With improved management of these tumors, there are more survivors with long-term sequelae of radiation and chemotherapy including growth failure. The aim of this study was to assess growth prospectively in children with nonpituitary-related primary brain tumors.

Methods.  Forty-one children 3.1 to 13.8 years of age diagnosed consecutively between 1989 and 1992 with a primary nonpituitary-related brain tumor were studied.

Results.  Of 34 prepubertal children, 14 (41%) were diagnosed as having growth hormone (GH) deficiency. All 14 children were treated with cranial irradiation. During the first year from completion of brain tumor therapy, the annual height velocity of those children confirmed subsequently as being GH-deficient was 3.06 ± 1.19 cm compared with 5.29 ± 2.21 cm for those who were not GH-deficient. During the second year, the annual height velocity was 3.29 ± 1.14 cm per year for the GH-deficient group compared with 5.48 ± 1.24 cm per year for the non-GH-deficient group. All children with GH deficiency received cranial irradiation and chemotherapy. Two of 34 children developed precocious puberty. Primary hypothyroidism was diagnosed in 6 of 41 children (12%).

Conclusion.  We conclude that GH deficiency and primary hypothyroidism are common after cranial irradiation and chemotherapy for nonpituitary-related brain tumors. Linear growth appears to reflect GH status accurately in children with brain tumors. Precise auxologic evaluation is simple and noninvasive and may reflect more accurately GH status than provocative GH testing. These findings reflect the need for prospective growth monitoring of children with nonpituitary-related brain tumors treated with cranial irradiation and chemotherapy. Early diagnosis of GH deficiency facilitates early initiation of GH therapy and optimization of final height.  Key words:  brain tumors, cranial irradiation, growth, growth hormone deficiency, hypothyroidism.




This article has been cited by other articles:


Home page
 CLIN PEDIATRHome page
N. Cakan and D. Kamat
Short Stature in Children: A Practical Approach for Primary Care Providers
Clinical Pediatrics, June 1, 2007; 46(5): 379 - 385.
[PDF]